Matthew Biegler
Stock Analyst at Oppenheimer
(3.45)
# 942
Out of 5,149 analysts
91
Total ratings
40.24%
Success rate
8.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $33.01 | +51.47% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $766.66 | +12.83% | 1 | Feb 2, 2026 | |
| RLAY Relay Therapeutics | Upgrades: Outperform | $14 | $9.85 | +42.13% | 7 | Jan 26, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $23.43 | +104.87% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $21.59 | +108.46% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $13.51 | +11.03% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $9.75 | +125.64% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $15.81 | +77.10% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.67 | +379.04% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.81 | +45.53% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.53 | +255.73% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $14.95 | +970.23% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $13.36 | +236.83% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $147.83 | -22.21% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $34.31 | +54.47% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.38 | +740.34% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.48 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.87 | +77.89% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $12.50 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.37 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $10.03 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.57 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.16 | - | 2 | Dec 22, 2022 |
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $33.01
Upside: +51.47%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $766.66
Upside: +12.83%
Relay Therapeutics
Jan 26, 2026
Upgrades: Outperform
Price Target: $14
Current: $9.85
Upside: +42.13%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $23.43
Upside: +104.87%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $21.59
Upside: +108.46%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $13.51
Upside: +11.03%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $9.75
Upside: +125.64%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $15.81
Upside: +77.10%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.67
Upside: +379.04%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.81
Upside: +45.53%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.53
Upside: +255.73%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $14.95
Upside: +970.23%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $13.36
Upside: +236.83%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $147.83
Upside: -22.21%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $34.31
Upside: +54.47%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.38
Upside: +740.34%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.48
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.87
Upside: +77.89%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $12.50
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.37
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $10.03
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.57
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.16
Upside: -